Company intelligence / Profile preview
Suzhou Baimai Biopharmaceutical
Suzhou, Jiangsu, Chinainnobm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Baimai Biopharmaceutical is developing a pipeline of oncology-focused drug candidates using biomaterial and immunotherapy platforms. Its lead asset BM‑201, a TLR7/TLR8 agonist, is in Phase 1 for advanced malignant solid neoplasms. Other programs are in early clinical or preclinical stages targeting various cancers including hepatocellular carcinoma and bladder cancer. No late-stage or commercialized products as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeBiologicImmunotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Suzhou Baimai Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Baimai Biopharmaceutical.